Drug Sales Trends for XALATAN

Payment Methods and Pharmacy Types for XALATAN (2003)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$71,749,167
INSIDE ANOTHER STORE	$38,932,943

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	641,108
INSIDE ANOTHER STORE	559,799

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$23,547,594
MEDICARE	$8,453,386

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for XALATAN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
XALATAN			2022
XALATAN			2021
XALATAN			2020
XALATAN			2019
XALATAN			2018

Last updated: September 8, 2026

Xalatan is a mature, off-patent ophthalmic product with limited branded growth potential. Market value is concentrated in generic latanoprost, while branded Xalatan revenue depends on residual physician preference, payer coverage, preservative-free positioning, and demand in markets with slower generic substitution. A normalized forecast indicates continued low-single-digit annual erosion for branded sales through 2030, with generic latanoprost retaining the larger commercial opportunity.

Xalatan Market Analysis and Sales Projections Through 2030

What is Xalatan and how is it used?

Xalatan is the branded ophthalmic solution containing latanoprost, a prostaglandin F2α analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as one drop in the affected eye once daily, typically in the evening. The product is marketed in a 0.005% ophthalmic solution formulation. [1]

Latanoprost lowers intraocular pressure by increasing uveoscleral outflow. Prostaglandin analogs remain a major first-line treatment category for glaucoma because of their once-daily dosing and strong pressure-lowering effect.

The commercial product has several limitations:

• The active ingredient is off patent in major markets.
• Generic latanoprost is widely available.
• The product is a mature therapy with limited ability to expand its labeled population.
• Branded sales are exposed to payer substitution and low-cost generic competition.
• Preservative-free and combination-product alternatives compete for the same patients.

How large is the Xalatan and latanoprost market?

Public companies generally do not disclose current standalone Xalatan revenue. Pfizer historically reported Xalatan as a major ophthalmology product, with annual sales near or above $1 billion before broad generic erosion. The product lost substantial value after generic latanoprost entered the U.S. market in 2011. [2]

The relevant market now has three segments:

Segment	Commercial position	Growth outlook
Branded Xalatan	Residual brand demand, selected international markets	Declining
Generic latanoprost	Dominant volume supplier	Stable to modest growth
Competing glaucoma products	Travoprost, bimatoprost, timolol combinations, newer agents	Mixed

The commercial value of the total latanoprost market is materially larger than current Xalatan brand sales. Generic manufacturers compete primarily on price, supply reliability, preservative options, bottle design, and formulary access.

Glaucoma prevalence supports durable unit demand. The National Eye Institute estimates that millions of U.S. adults have glaucoma, with many cases remaining undiagnosed. Aging populations in North America, Europe, Japan, China, and other markets support long-term prescription volume even as per-unit pricing declines. [3]

What are the Xalatan sales projections from 2025 to 2030?

The following forecast normalizes 2024 branded Xalatan net sales to an index of 100 because audited current product-level revenue is not publicly reported. The model assumes no major label expansion, no meaningful patent recovery, continued generic substitution, and stable glaucoma prevalence.

Year	Base case index	Downside index	Upside index
2024	100	100	100
2025	95	88	100
2026	90	77	98
2027	85	68	96
2028	81	60	94
2029	77	53	92
2030	73	47	90

The base case implies a compound annual decline of approximately 5% from 2024 through 2030. The downside case reflects accelerated payer exclusion, further international generic penetration, or product discontinuation in selected markets. The upside case assumes stronger branded retention in emerging markets and slower substitution in markets where physician dispensing or branded prescribing remains common.

For an investor or licensing model, the dollar conversion is straightforward:

2024 Xalatan net sales assumption	2030 base-case sales	2030 downside sales	2030 upside sales
$50 million	$36.5 million	$23.5 million	$45.0 million
$100 million	$73.0 million	$47.0 million	$90.0 million
$200 million	$146.0 million	$94.0 million	$180.0 million

These projections apply to branded Xalatan sales, not the total market for generic and branded latanoprost.

When did Xalatan lose exclusivity?

Xalatan’s principal U.S. market protection ended in the early 2010s. The FDA approved generic latanoprost products in 2011, allowing meaningful substitution after the core protection period ended. [4]

Milestone	Approximate timing	Commercial effect
FDA approval of Xalatan	1996	U.S. launch
Core U.S. patent protection	Expired around 2010-2011	Generic entry became possible
First significant U.S. generic approvals	2011	Rapid price and share erosion
Current status	Off patent	Brand has no durable U.S. exclusivity

The Orange Book remains the relevant source for historical patent and exclusivity information associated with NDA 020597. Current commercial risk is not driven by an active Xalatan patent barrier. [5]

What patents protect Xalatan today?

No active U.S. patent estate is expected to provide meaningful exclusivity for the original Xalatan product. The relevant historical protection covered latanoprost and its ophthalmic use. Those rights expired before the current generic market structure developed.

Formulation patents

Xalatan’s original formulation contains latanoprost in an ophthalmic vehicle with benzalkonium chloride as a preservative. Generic manufacturers have been able to commercialize substantially equivalent formulations through the abbreviated new drug application pathway.

Potentially differentiating formulation areas include:

• Preservative-free latanoprost;
• Multidose preservative-free containers;
• Improved bottle-drop accuracy;
• Extended room-temperature stability;
• Combination products;
• Reduced ocular-surface irritation.

These technologies may have separate patent protection, but they do not restore exclusivity to the original Xalatan product.

Method-of-use patents

The original glaucoma and ocular-hypertension use claims are mature. New method-of-use patents could cover treatment sequencing, adherence improvement, selected patient subgroups, or combination therapy, but they would have limited ability to block generic latanoprost for the original approved indication.

What is the FDA and Orange Book status of Xalatan?

Xalatan is an FDA-approved prescription ophthalmic product. Its U.S. regulatory reference is NDA 020597. Generic latanoprost products have been approved through ANDAs referencing the branded product. [1, 5]

The key regulatory distinction is between:

• The original Xalatan NDA;
• Generic latanoprost ANDAs;
• Brand or generic combination products;
• Preservative-free latanoprost formulations;
• Other prostaglandin analogs with separate NDAs.

Because the product is small-molecule and off patent, biosimilar risk does not apply. The relevant competitive risk is generic substitution, not biosimilar entry.

Which companies compete with Xalatan and generic latanoprost?

Competition is divided between generic suppliers and branded glaucoma products.

Generic latanoprost competitors

Major generic ophthalmology companies that have participated in the U.S. market include:

• Viatris;
• Teva Pharmaceutical Industries;
• Sandoz;
• Apotex;
• Mylan, now part of Viatris;
• Bausch + Lomb;
• Hikma;
• Amneal;
• Dr. Reddy’s Laboratories;
• Zydus Lifesciences.

Supplier participation varies by country and time. Generic pricing is sensitive to manufacturing capacity, FDA inspection status, shortages, contract pharmacy purchasing, and wholesaler concentration.

Branded therapeutic competitors

Relevant branded and specialty competitors include:

• Lumigan, containing bimatoprost;
• Travatan Z, containing travoprost;
• Rocklatan, containing netarsudil and latanoprost;
• Vyzulta, containing latanoprostene bunod;
• Cosopt and related fixed combinations;
• Rhopressa, containing netarsudil.

Xalatan’s main competitive advantage is familiarity and once-daily dosing. Its main disadvantages are generic availability and limited differentiation from low-cost latanoprost products.

How strong is the Xalatan patent estate?

The current patent strength is low. The original composition, use, and formulation protections have expired or no longer provide meaningful commercial exclusion in the United States.

Patent factor	Assessment
Core active ingredient protection	Expired
Original ophthalmic-use protection	Expired or commercially non-blocking
Original formulation protection	Expired or non-exclusive
Current U.S. Orange Book leverage	Low
Generic Paragraph IV exposure	Historical rather than current
Manufacturing complexity	Moderate
Ability to block generic substitution	Minimal

The remaining business risk is operational rather than patent-driven. Sterile ophthalmic manufacturing requires validated aseptic processes, container-closure controls, stability data, and regulatory compliance. Those requirements can limit the number of reliable suppliers, but they do not create durable exclusivity for Xalatan.

What patent litigation and Paragraph IV challenges affected Xalatan?

The major legal event was the wave of ANDA activity associated with generic latanoprost entry around the end of the original patent term. Paragraph IV certifications are relevant when a generic applicant claims that a listed patent is invalid, unenforceable, or not infringed. [5]

For Xalatan, that litigation cycle is commercially historical. There is no current litigation pathway that would materially restore brand exclusivity for the original product. Any new dispute would more likely concern:

• A new preservative-free formulation;
• A delivery device;
• A combination product;
• Manufacturing or supplier rights;
• A separate latanoprost-based product.

No widely reported settlement agreement currently provides Xalatan with a material market-protection advantage.

What generic entry risks exist for Xalatan?

Generic entry risk is already realized rather than prospective. The principal risks to the remaining brand business are:

1. Formulary exclusion or higher patient copay for branded Xalatan.
2. Low-cost substitution at the pharmacy.
3. Additional generic suppliers entering markets with limited current competition.
4. Hospital and government procurement shifting to tender-based purchasing.
5. Physician movement toward preservative-free or combination therapies.
6. Supply interruptions by a branded or generic manufacturer.

Generic supply concentration can create temporary pricing opportunities, but these are unlikely to change the long-term direction of branded sales.

How does Xalatan compare with competing glaucoma drugs?

Product	Active ingredient	Dosing	Patent position	Commercial profile
Xalatan	Latanoprost	Once daily	Off patent	Mature brand
Generic latanoprost	Latanoprost	Once daily	Off patent	Volume leader
Lumigan	Bimatoprost	Once daily	Brand and formulation rights vary	Premium prostaglandin
Travatan Z	Travoprost	Once daily	Mature branded product	Alternative prostaglandin
Vyzulta	Latanoprostene bunod	Once daily	Active product-specific rights may apply	Differentiated nitric-oxide pathway
Rocklatan	Netarsudil/latanoprost	Once daily	Product-specific patents	Combination therapy

Xalatan is strongest where low acquisition cost and physician familiarity matter. It is weakest in markets with aggressive generic substitution or where ocular-surface tolerability and preservative-free delivery influence prescribing.

What licensing and commercial opportunities exist for Xalatan?

Licensing upside is limited for the original brand. More attractive opportunities involve latanoprost-related technologies rather than Xalatan itself:

• Regional commercialization rights in markets with limited generic penetration;
• Preservative-free ophthalmic delivery;
• Combination products;
• Multidose container systems;
• Contract manufacturing and supply agreements;
• Emerging-market distribution partnerships.

A licensing valuation should rely on net sales after generic discounts, not historical peak Xalatan revenue. Royalty assumptions should also reflect the absence of patent exclusivity and the possibility of direct generic competition.

What is the geographic outlook for Xalatan sales?

The United States and Western Europe offer limited branded growth. Generic penetration is high, payer leverage is strong, and pharmacy substitution is routine.

Higher residual brand opportunity may exist in:

• Latin America;
• Southeast Asia;
• Middle Eastern markets;
• Selected African markets;
• Countries where branded prescribing remains common;
• Markets where generic regulatory approval or distribution is fragmented.

China and India provide large patient populations but remain highly price-sensitive. Local manufacturing and registration requirements can reduce the value of imported branded supply.

Key Takeaways

• Xalatan is a mature, off-patent latanoprost product.
• Generic latanoprost, rather than branded Xalatan, captures most current market volume.
• Branded Xalatan sales are likely to decline at roughly 5% annually in the base case through 2030.
• The U.S. patent and Orange Book position does not provide meaningful current exclusivity.
• Biosimilar risk is irrelevant because Xalatan is a small-molecule drug.
• The main barriers are sterile manufacturing, supply reliability, distribution, and regulatory compliance.
• Commercial upside is greater in preservative-free delivery, combination products, and selected international markets than in the original branded formulation.
• Licensing valuations should use current residual brand economics rather than historical peak sales.

FAQs About Xalatan Market Size, Patents, and Sales

Is Xalatan still sold in the United States?

Xalatan remains an FDA-approved reference product, but generic latanoprost is widely available and usually receives stronger payer preference.

What is the largest revenue opportunity related to Xalatan?

The largest opportunity is the broader generic latanoprost market, not the branded Xalatan product. Brand revenue is concentrated in residual prescribing and selected international markets.

Does Xalatan have a patent extending beyond 2030?

No active original Xalatan patent is expected to provide U.S. exclusivity through 2030. Any later patent opportunity would need to cover a new formulation, device, combination, or method of use.

Can a company launch a generic version of Xalatan?

Yes. Generic latanoprost products have been approved through the ANDA pathway, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, and sterile ophthalmic production.

Is preservative-free latanoprost a major threat to Xalatan?

It is a potential premium threat, particularly for patients with ocular-surface disease or intolerance to benzalkonium chloride. Its commercial impact depends on price, reimbursement, bottle technology, and clinical differentiation.

References

1. U.S. Food and Drug Administration. (2019). Xalatan prescribing information. FDA Drugs@FDA database.
2. Pfizer Inc. (2011). Annual report 2011. Pfizer Investor Relations.
3. National Eye Institute. (2023). Glaucoma data and statistics. National Institutes of Health.
4. U.S. Food and Drug Administration. (2011). FDA approves first generic latanoprost ophthalmic solution. FDA.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.